neck fracture) and the Hungarian Diagnosis Related Groups. Patients with polytrauma or severe comorbidities were excluded. Our retrospective analysis includes patients under 60 with femoral neck fracture identified with Social Security Identification number (TAJ) and discharged in 2000. RESULTS: A total of 518 patients met the selection criteria and 23.7% of them (N = 123) had impaired ability to work. The proportion of patients with impaired ability to work was 41.3% in patients with further treatment, 50% in patients with secondary prosthesis and 20% in patients with one definitive treatment. The proportion of patients with impaired ability to work according to the method of primary surgery was 27.1% in arthroplasty, 23.7 in screw fixation and 20.6% in DHS. A total of 16.3% of disabled patients received rehabilitation treatment. The proportion of disabled patients increased in higher age groups. We found higher than national average disability ratio in regions with higher unemployment rate and lower employment rate. CONCLUSIONS:
We found higher impaired ability to work ratio in patients with complications receiving further treatment and in arthroplasty. In order to reduce the impaired ability to work, the sick-pay period should be used more efficiently. The frequency of impaired ability to work is not only a health related problem but it is an effect of social and economic processes.
OSTEOPOROSIS-Health Care Use & Policy Studies

POS8 PRICE AND UTILIZATION OF OSTEOPOROSIS MEDICATIONS IN U.S. MEDICAID PROGRAMS
Knight D, Guo JJ, Shiyanbade H, Kelton CM University of Cincinnati, Cincinnati, OH OBJECTIVES: Approximately eight million women and two million men in the U.S. suffer from osteoporosis, a disease that causes over 1.5 million fractures each year. The cost to Medicaid for anti-osteoporosis medications topped $85 million in the first quarter of 2004. The objective of this study is to analyze price, cost, utilization, and market shares of oral anti-osteoporosis medications in U.S. Medicaid programs, with the specific purpose of assessing interbrand competition in a tightly oligopolistic market. METHODS: There are five oral medications for osteoporosis, including Didronel® (etidronate), Skelid® (tiludronate), Actonel® (risedronate), Fosamax® (alendronate), and Evista® (raloxifene). Data from the First DataBank® were used to calculate the monthly Average Wholesale Price (AWP) per daily dose for each drug over the period 1990-2004. Data from the National Medicaid Pharmacy claims were used to calculate quarterly drug prescriptions, market shares, and reimbursements over essentially the same time period. RESULTS: The three most frequently prescribed drugs are alendronate (utilization reached 600,000 scripts in the 1st quarter 2004); risedronate whose use increased from 90 scripts in the 2nd quarter 1999 to 400,000 in the 1st quarter 2004; and raloxifene with utilization of 190,000 scripts in the 1st quarter 2004. Each of these drugs has an AWP per daily dose in the $2.00 to $4.00 range. Interestingly, the Medicaid cost per prescription for risedronate decreased from $300 in 1999 to $80 in 2004. Though not widely prescribed, the AWP for tiludronate is much higher than for its competitors at $15.00 per daily dose. CONCLUSIONS: There is no indication that market shares or prices of branded medications are responding to new entry in the anti-osteoporosis drug market. Movement in prices and utilization are driven much more by dosage and compliance issues.
POS9 TRENDS IN THE CLINICAL MANAGEMENT OF FRAGILE FRACTURE BEFORE AND AFTER THE NEW HEDIS OSTEOPOROSIS MANAGEMENT MEASURE IN A MEDICARE POPULATION
Foster S 1 , Foley K 2 , Baser O 3 , Meadows E 1 , Long SR 3 1 Eli Lilly and Company, Indianapolis, IN, USA, 2 Thomson Medstat, Philadelphia, PA, USA, 3 Thomson Medstat, Chicago, IL, USA OBJECTIVE: To examine the trend in clinical management of patients with fragile fractures before and after the implementation of the Health Plan Employer Data and Information Set (HEDIS) osteoporosis measure. METHODS: Two cohorts of Medicare Beneficiaries with continuous enrollment for at least 18 months and a fracture during the measurement year and no use of osteoporosis medication or BMD screening in the preceding 12 months were identified in the MarketScan Medicare Supplemental and COB database for the measurement years 2000-2005. Per HEDIS, each measurement year began on July 1st of the preceding year and continues through June 30th of the measurement year. The first cohort consisted of women aged 67 and older, while the second cohort consisted of men and women aged 65 and older. Fractures were identified according to HEDIS definitions. Clinical management was assessed by the presence of a claim for BMD screening and/or a prescription for a bisphosphonate or other osteoporosis-specific medication in the year following the fracture. Adjusted rates of change in screening and treatment were estimated using multivariate logistic regression. RESULTS: In the measurement year 2000, 8.4% of Cohort 1 underwent BMD screening and 11.2% received pharmacological treatment. For Cohort 2, the rates were 6.5% and 8.3%, respectively. By 2005, BMD screening had increased by 21% and treatment increased by 15% for Cohort 1. For Cohort 2, the rates increased by 42% and 22%, respectively. After adjusting for patient age, sex, fracture location, provider specialty, geographic region and capitated versus non-capitated health plan, the rates for screening and treatment had increased by 21% and 15% for Cohort 1, and by 41% and 15% for Cohort 2. CON-CLUSION: While slow progress has been made in the clinical management of fracture since the implementation of the HEDIS osteoporosis measure, there is still an opportunity for significant improvement.
OSTEOPOROSIS-Methods and Concepts
POS10 TREATMENT PATTERNS AND RESOURCE UTILIZATION IN PATIENTS WITH PAGET'S DISEASE TREATED WITH RISENDRONATE
Doyle J 1 , Stern L 1 , Dolgitser M 1 , Katz LM 1 , Omar M 2 , Kahler K 2 1 Analytica International, New York, NY, USA, 2 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA OBJECTIVES: After the recommended two-month treatment course of risedronate for the treatment of Paget's disease, patients should be followed to assess the need for re-treatment. We examined real-world treatment patterns and resource utilization in patients treated with risedronate for Paget's disease. METHODS: Patients enrolled in a nationally representative, multi-managed care plan claims database (1998) (1999) (2000) (2001) (2002) (2003) (2004) ; Phar-Metrics) with a diagnosis of Paget's disease (>1 ICD-9 code), >1 risedronate prescription at the Paget's dose (30 mg; daily dosing), no osteoporosis, and >1 year of follow-up after initial risedronate therapy were identified. For this cohort, we evaluated: 1) Proportion of patients with risedronate use >1 month after the recommended treatment regimen in the approved label (i.e., additional use); 2) Proportion of patients without risedronate prescription (i.e., gap) from days 61 to 180, followed by use after that (i.e., retreatment); 3) Annualized resource use stratified by retreatment status. RESULTS: Of the 45 patients who met study inclusion criteria, mean age was 61.8 and 62.2% were male. 46.7% of patients (n = 21) had medication use >1 month after the recommended treatment regimen. 73.3% (n = 33) had a gap in treatment, and of these, 24.2% (n = 8) were retreated after the gap. Annualized resource utilization (mean (SD)) for not retreated vs. retreated patients respectively was: Physician visits: 2.0 (2.0) vs. 4.2 (3.9), p = 0.16; Specialist visits: 1.0 (2.1) vs. 2.7 (2.9), p = 0.16; SAP tests: 0.3 (0.8) vs. 0.8 (2.8), p = 0.32; and Bisphosphonate prescriptions: 1.7 (2.3) vs. 4.2 (3.9), p = 0.12. CONCLUSIONS: This analysis of real-world treatment patterns and resource use in risedronate-treated patients suggests a large extent of risedronate use beyond approved label recommendations and high retreatment rates, as well as higher resource use in those retreated. Larger studies are warranted to further understand treatment patterns and associated resource utilization in Paget's disease patients.
POS11 THE USE OF INDIVIDUAL RISKS RATHER THAN POPULATION AVERAGES IN COST-EFFECTIVENESS MODELING
Van Staa TP 1 , Geusens P 2 , Boonen A 2 , Leufkens HG 3 , Cooper C 4 1 General Practice Research Database, London, UK, 2 University Hospital, Maastricht, The Netherlands, 3 Utrecht University, Utrecht, The Netherlands, 4 University of Southampton, Southampton, UK OBJECTIVES: Cost-effectiveness analyses are routinely based on data from group averages, restricting its generalizibility to those with below-or above-average risk. A pharmaco-economic model was developed that used individualised risks, taking as example bisphosphonates and prevention of fractures. METHODS: Data were obtained from a research database of general practitioners, comprising a sample of the UK general population of women >50 years (N = 330,000). Individual mortality and hip, vertebral, and other osteoporotic fracture risks were estimated by age, sex, body mass index, smoking and other clinical risk factors. Estimates on costs, EQ5D utilities and treatment efficacy were obtained from a UK national report (NICE) and outcomes were simulated over a ten-year period. RESULTS: There was a large variability in the cost-effectiveness with clinical risk factors. At age 60-69, the cost per QALY gained was ≤136 k in women with low fracture risk but ≤36 k with high fracture risk (data for women without fracture history). Patients with low body mass index (<20) had considerable better cost-effectiveness than patients with high BMI (≥26) (≤23 k versus ≤71 k at age 60-79 in women without fracture history). The same was found for different diseases such as rheumatoid arthritis or inflammatory bowel disease. Using a cost-acceptability ratio of ≤30 k per QALY gained, bisphosphonates became cost-effective for patients with a five-year risk of 9.3% (95% CI 8.0-10.5%) for osteoporotic fractures and of 2.1% (95% CI 1.5-2.7%) for hip fractures. Including bone mineral density in the risk assessment, the cost per QALY gained was ≤35 k in women at age 60 with a fracture history and a T-score of -2.5 (at age 80, this was ≤3 k). CONCLUSIONS: A pharmaco-economic model based on individual long-term risks (as derived from a health care database) can improve the targeting in a cost-effective manner of therapy to patients.
OSTEOPOROSIS-Patient Reported Outcomes
POS12 PATIENT ADHERENCE WITH BISPHOSPHONATES AT 6 MONTHS: A RETROSPECTIVE COHORT STUDY
Borisov N, Worley K, Agnew J, Steinbuch M P&G Pharmaceuticals, Inc, Mason, OH, USA OBJECTIVES: To assess patient adherence with bisphosphonates at 6 months of therapy utilizing an integrated administrative, medical and pharmacy claims database. METHODS: A retrospective cohort study was conducted among 128,362 women, 45 years of age and older, with a new (index) prescription for risedronate (35 mg/week) or alendronate (35 mg/week or 70 mg/week) between May 1, 2002, and December 31, 2003 . All eligible patients were required to be continuously enrolled for the six months preceding and the 12 months following the index date and to have filled at least 2 continuous bisphosphonate prescriptions, as defined below. The six-month history was used to assess baseline clinical characteristics, including fracture history, gastrointestinal conditions, hospitalizations, and glucocorticoid use. Adherence with therapy was then assessed for the first 6 months of bisphosphonate treatment. Patient adherence was defined as continuous refilling of the weekly bisphosphonate treatment with no gaps exceeding 90 days during the follow-up period. RESULTS: The average bisphosphonate user in this study was aged 64 years; 78% initiated with alendronate and 22% with risedronate. Almost 4% had a history of fragility fractures (vertebral and/or non-vertebral) and 18% used oral glucocorticoids during the study period. At 6 months, 71% of bisphosphonate patients were adherent with therapy. An additional 22% discontinued, and subsequently resumed treatment after a mean treatment gap of 164 days. The following patient characteristics were correlated with a higher likelihood of therapy discontinuation: younger age, GI event after the index date, oral glucocorticoid use, and history of GI events, hospitalization, or fracture. CONCLUSIONS: This study demonstrates that seven in ten new bisphosphonate users remained on therapy at six months after treatment initiation. An additional two in ten patients resumed therapy after a mean treatment gap of five months. Overall, the majority of patients who initiated bisphosphonates were adherent after the first six months of treatment.
POS13 COMPLIANCE, DISCONTINUATION, AND SWITCHING OF OSTEOPOROSIS TREATMENT IN LOUISIANA MEDICAID POST-MENOPAUSAL WOMEN
Trivedi DN, Blake S, Thibodeaux SM, Lawrence L The University of Louisiana at Monroe, Monroe, LA, USA OBJECTIVES: To determine the rates of compliance; discontinuation; and switching of treatment with bisphosphonates, calcitonin, estrogens, parathyroid hormones, and raloxifene in Louisiana Medicaid post-menopausal women with diagnosis of osteoporosis and/or fracture. METHODS: Medical and pharmacy administrative claims data obtained from the Louisiana Department of Health and Hospitals were used for the study. The data contain paid claims for all Louisiana Medicaid recipients. Women age 50 and older diagnosed with osteoporosis and/or a fracture between July 1, 2002 and June 30, 2003 and continuously eligible 12 months prior through 24 months after their initial diagnosis were included in the study. Women with Medicare eligibility and those who received a prescription for osteoporosis and/or fracture 12 months prior were excluded. There were 1772 women who met the inclusion criteria. Claims data on these women were studied for two years from the date of their initial diagnosis. Women were considered compliant if the difference between their fill dates did not exceed 45 days. Women were considered discontinuers if they filled prescriptions only once in the two-year study period. Recipients were considered switchers if they switched from one drug to another, single to combination therapy, or combination to single therapy. RESULTS: Of the 1772 in the study group, 28% (500) received treatment, and of those, 57% were on a single drug, 22% on multiple drugs, and 21% discontinued treatment. The compli-
